Skip to content

Study · Systematic review · n = 8,628 · 2025

18 results

Liraglutide for adults living with obesity.

Meza N, Bracchiglione J, Escobar Liquitay CM, Madrid E, Varela LB, Guo Y, Urrútia G, Er S, Tiller S, Shokraee K, Alvarez Busco F, Solà I and 4 more

Show all authors

Ocara Vargas M, Novik A V, Poloni D, Franco JV

The Cochrane database of systematic reviews30 Oct 2025Cited by 1 (Europe PMC)

PMID41161684 (opens in a new tab)DOI10.1002/14651858.cd016017 (opens in a new tab)PepBankPUB-41161684
Publisher pagePubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with obesity, the review rated the effect of liraglutide on adverse events leading to withdrawal versus placebo at medium-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain how much liraglutide raises the number of people who stop treatment because of side effects.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdverse events leading to withdrawal, medium term
    Study

    n = 8,628

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.98 ratio
    adverse events leading to withdrawal

    Source sentences

    Summary
    and on adverse events leading to withdrawal (RR 1.98, 95% CI 1.30 to 3.02; I² = 47%; 19 studies, 8628 participants
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  2. 02HumanSystematic reviewSafety outcome

    In adults with obesity, liraglutide may increase serious adverse events versus placebo at medium-term follow-up (low-certainty evidence).

    In plain wordsIn adults with obesity, liraglutide may cause more serious side effects than placebo over 26 to 68 weeks. The evidence is weak.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerious adverse events, medium term
    Study

    n = 8,487

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.2 ratio
    serious adverse events

    Source sentences

    Summary
    Liraglutide may increase any adverse events (RR 1.07, 95% CI 1.04 to 1.11; I² = 28%; 16 studies, 8147 participants; low-certainty evidence) and serious adverse events (RR 1.20, 95% CI 1.00 to 1.43; I² = 0%; 20 studies, 8487 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with obesity, the review rated the effect of liraglutide on mortality versus placebo at medium-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain whether liraglutide changes the number of deaths compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMortality, medium term
    Study

    n = 8,224

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    0.44 ratio
    mortality

    Source sentences

    Summary
    The evidence is very uncertain about the effect of liraglutide on mortality (RR 0.44, 95% CI 0.08 to 2.25; I² = 0%; 18 studies, 8224 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  4. 04HumanSystematic reviewSafety outcome

    In adults with obesity, liraglutide may increase any adverse events versus placebo at medium-term follow-up (low-certainty evidence).

    In plain wordsIn adults with obesity, liraglutide may cause more side effects of any kind than placebo over 26 to 68 weeks. The evidence is weak.

    Peptide
    Liraglutide
    Outcome
    IncreaseAny adverse events, medium term
    Study

    n = 8,147

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.07 ratio
    any adverse events

    Source sentences

    Summary
    Liraglutide may increase any adverse events (RR 1.07, 95% CI 1.04 to 1.11; I² = 28%; 16 studies, 8147 participants
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  5. 05HumanSystematic reviewSafety outcome

    In adults with obesity, the review rated the effect of liraglutide on non-serious adverse events versus placebo at medium-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain how much liraglutide raises non-serious side effects compared with placebo over 26 to 68 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseNon-serious adverse events, medium term
    Study

    n = 7,440

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.14 ratio
    non-serious adverse events

    Source sentences

    Summary
    The evidence is very uncertain about the effects of liraglutide on non-serious adverse events (RR 1.14, 95% CI 1.05 to 1.24; I² = 76%; 17 studies, 7440 participants
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide likely increased the number of people achieving 5% weight reduction versus placebo at medium-term follow-up (moderate-certainty evidence).

    In plain wordsIn adults with obesity, more people lost 5% of their weight with liraglutide than with placebo over 26 to 68 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion achieving 5% weight reduction, medium term
    Study

    n = 6,651

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    2.1 ratio
    5% weight reduction

    Source sentences

    Summary
    but likely increases the number of people achieving 5% weight reduction (risk ratio (RR) 2.10, 95% CI 1.80 to 2.45; I2 = 78%; 18 studies, 6651 participants; moderate-certainty evidence)
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide reduced percentage body weight versus placebo at medium-term follow-up, but the review rated the evidence as very uncertain.

    In plain wordsIn adults with obesity, liraglutide lowered body weight more than placebo over 26 to 68 weeks. The review rated the evidence as very uncertain.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage weight change from baseline, medium term
    Study

    n = 6,050

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    mean difference
    −4.72%
    liraglutide vs placebo, medium term

    Source sentences

    Summary
    The evidence is very uncertain about the effect of liraglutide on percentage weight change from baseline (mean difference (MD) -4.72, 95% confidence interval (CI) -5.32 to -4.12; I2 = 57%; 16 studies, 6050 participants; very low-certainty evidence)
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide likely gave little to no clinically meaningful difference in MACE versus placebo at medium-term follow-up (moderate-certainty evidence).

    In plain wordsIn adults with obesity, liraglutide likely made little to no difference to major heart events compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor adverse cardiovascular events (MACE), medium term
    Study

    n = 5,762

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    risk ratio
    0.86 ratio
    MACE

    Source sentences

    Summary
    Liraglutide likely results in little to no clinically meaningful difference in MACE (RR 0.86, 95% CI 0.66 to 1.10; I² = 0%; 6 studies, 5762 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  9. 09HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide likely gave little to no difference in IWQOL-Lite-CT physical function versus placebo at medium-term follow-up.

    In plain wordsIn adults with obesity, liraglutide likely made little to no difference to physical function quality of life compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeQuality of life (IWQOL-Lite-CT physical function), medium term
    Study

    n = 3,733

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 26 to 68 weeksAs given in this study (human).

    Measurements

    mean difference
    2.9 points
    IWQOL-Lite-CT physical function

    Source sentences

    Summary
    Liraglutide likely results in little to no difference in quality of life measured by the IWQOL-Lite-CT physical function (MD 2.90, 95% CI -0.08 to 5.89; I² = 58%; 6 studies, 3733 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  10. 10HumanSystematic reviewSafety outcome

    In adults with obesity, the review rated the effect of liraglutide on any adverse events versus placebo at long-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain whether liraglutide changes the rate of side effects of any kind over 104 to 162 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeAny adverse events, long term
    Study

    n = 2,640

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.19 ratio
    any adverse events

    Source sentences

    Summary
    The evidence is very uncertain about the effect of liraglutide on any adverse events (RR 1.19, 95% CI 0.93 to 1.52; I² = 93%; 2 studies, 2640 participants; very low-certainty evidence) and on non-serious adverse events (RR 1.19, 95% CI 0.94 to 1.51; I² = 93%; 2 studies, 2640 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  11. 11HumanSystematic reviewSafety outcome

    In adults with obesity, the review rated the effect of liraglutide on non-serious adverse events versus placebo at long-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain whether liraglutide changes the rate of non-serious side effects over 104 to 162 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeNon-serious adverse events, long term
    Study

    n = 2,640

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.19 ratio
    non-serious adverse events

    Source sentences

    Summary
    The evidence is very uncertain about the effect of liraglutide on any adverse events (RR 1.19, 95% CI 0.93 to 1.52; I² = 93%; 2 studies, 2640 participants; very low-certainty evidence) and on non-serious adverse events (RR 1.19, 95% CI 0.94 to 1.51; I² = 93%; 2 studies, 2640 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  12. 12HumanSystematic reviewSafety outcome

    In adults with obesity, liraglutide may increase serious adverse events versus placebo at long-term follow-up (low-certainty evidence); the interval includes no difference.

    In plain wordsIn adults with obesity, liraglutide may raise serious side effects over 104 to 162 weeks, but the result could also mean no difference.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious adverse events, long term
    Study

    n = 2,640

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.2 ratio
    serious adverse events

    Source sentences

    Summary
    Liraglutide may increase serious adverse events (RR 1.20, 95% CI 0.98 to 1.48; I² = 0%; 2 studies, 2640 participants; low-certainty evidence) and adverse events leading to withdrawal (RR 2.16, 95% CI 1.59 to 2.93; I² = 0%; 2 studies, 2640 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  13. 13HumanSystematic reviewSafety outcome

    In adults with obesity, liraglutide may increase adverse events leading to withdrawal versus placebo at long-term follow-up (low-certainty evidence).

    In plain wordsIn adults with obesity, more people may stop liraglutide because of side effects than stop placebo over 104 to 162 weeks. The evidence is weak.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdverse events leading to withdrawal, long term
    Study

    n = 2,640

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    2.16 ratio
    adverse events leading to withdrawal

    Source sentences

    Summary
    Liraglutide may increase serious adverse events (RR 1.20, 95% CI 0.98 to 1.48; I² = 0%; 2 studies, 2640 participants; low-certainty evidence) and adverse events leading to withdrawal (RR 2.16, 95% CI 1.59 to 2.93; I² = 0%; 2 studies, 2640 participants; low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  14. 14HumanSystematic reviewEfficacy outcome

    In adults with obesity, the review rated the effect of liraglutide on mortality versus placebo at long-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain whether liraglutide changes the number of deaths compared with placebo over 104 to 162 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeMortality, long term
    Study

    n = 2,640

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    0.81 ratio
    mortality

    Source sentences

    Summary
    The evidence is very uncertain about the effect of liraglutide on mortality (RR 0.81, 95% CI 0.16 to 4.17; I² = 0%; 2 studies, 2640 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  15. 15HumanSystematic reviewEfficacy outcome

    In adults with obesity, the review rated the effect of liraglutide on MACE versus placebo at long-term follow-up as very uncertain.

    In plain wordsIn adults with obesity, it is very uncertain whether liraglutide changes major heart events over 104 to 162 weeks. Only one study reported this.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor adverse cardiovascular events (MACE), long term
    Study

    n = 2,248

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    0.83 ratio
    MACE

    Source sentences

    Summary
    The evidence is very uncertain about the effect of liraglutide on MACE (RR 0.83, 95% CI 0.20 to 3.46; I² not applicable; 1 study, 2248 participants; very low-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  16. 16HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide reduced percentage body weight versus placebo at long-term follow-up; the review judged the difference as possibly not clinically meaningful (low-certainty evidence).

    In plain wordsIn adults with obesity, liraglutide lowered body weight more than placebo over 104 to 162 weeks. The review judged the difference as possibly small.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage weight change from baseline, long term
    Study

    n = 1,262

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    mean difference
    −4.34%
    liraglutide vs placebo, long term

    Source sentences

    Summary
    Liraglutide may result in little to no clinically meaningful difference in percentage weight change from baseline (MD -4.34, 95% CI -5.26 to -3.43; I² = 0%; 2 studies, 1262 participants; low-certainty evidence)
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  17. 17HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide likely increased the number of participants achieving 5% weight reduction versus placebo at long-term follow-up (moderate-certainty evidence).

    In plain wordsIn adults with obesity, more people lost 5% of their weight with liraglutide than with placebo over 104 to 162 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion achieving 5% weight reduction, long term
    Study

    n = 1,262

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    risk ratio
    1.78 ratio
    5% weight reduction

    Source sentences

    Summary
    and likely increases the number of participants achieving 5% weight reduction (RR 1.78, 95% CI 1.51 to 2.09; I² = 0%; 2 studies, 1262 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.
  18. 18HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide likely gave little to no clinically meaningful difference in IWQoL-Lite-CT physical function versus placebo at long-term follow-up.

    In plain wordsIn adults with obesity, liraglutide likely made little to no meaningful difference to physical function quality of life compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeQuality of life (IWQoL-Lite-CT physical function), long term
    Study

    n = 863

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 104 to 162 weeksAs given in this study (human).

    Measurements

    mean difference
    3.81 points
    IWQoL-Lite-CT physical function

    Source sentences

    Summary
    Liraglutide likely results in little to no clinically meaningful difference in quality of life measured by the IWQoL-Lite-CT physical function (MD 3.81, 95% CI 1.03 to 6.59; I² not applicable; 1 study, 863 participants; moderate-certainty evidence).
    2 context sentences
    Summary · context
    We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months.
    Summary · context
    We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.